CrushSCI.com
194.6平均天数
195.5中位天数
21最短天数
423最长天数
7462025发文量

Paper Review Records

全部论文审稿周期

20 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

182 天

Generational gains in cognitive capacity and dementia incidence rates in Western countries

作者
Anders M. Fjell; Edvard O. S. Grødem; Gabriela Lunansky; Didac Vidal-Piñeiro; Ole Rogeberg; Kristine B. Walhovd展开收起
作者单位
1. Center for Lifespan Changes in Brain and Cognition, University of Oslo, Oslo, Norway; 2. Computational Radiology and Artificial Intelligence, Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway; 3. Department of Epidemiology and Data Science, Amsterdam University Medical Centers (VUmc), Amsterdam, Netherlands; 4. Ragnar Frisch Centre for Economic Research, Oslo, Norway展开收起
PDF源文件 DOI 网页
232 天

An open agentic AI co-scientist for clinical and biomedical discovery

作者
Kaleigh F. Roberts; Zachary B. Abrams; Luca Cappelletti; Mahdi Moqri; Nicholas Heugel; J. Harry Caufield; Mathieu Bourdenx; Yan Li; Jineta Banerjee; Luca Foschini; Diego Galeano; Nomi L. Harris; Melody Li; Kejun Ying; Justin A. Melendez; Nicolas R. Barthélemy; James G. Bollinger; Yingxin He; Vitaliy Ovod; Tammie L. S. Benzinger; Shaney Flores; Brian A. Gordon; Taylor Pedersen; Jinsheng Yu; Brendan P. Lucey; Erik S. Musiek; Sarah A. Naylor; Adegoke A. Ojewole; Mukta Phatak; Donald L. Elbert; Sarah Biber; Eric C. Landsness; Christopher J. Mungall; Randall J. Bateman; Justin T. Reese展开收起
作者单位
1. Department of Pathology & Immunology, Washington University in St. Louis, St. Louis, USA; 2. Tracy Family SILQ Center, Washington University in St. Louis, St. Louis, USA; 3. Consortium for Biomedical Research & AI in Neurodegeneration (C-BRAIN), St. Louis, USA; 4. Institute for Informatics, Data Science, and Biostatistics, Washington University in St. Louis, St. Louis, USA; 5. Department of Biology, University of Fribourg, Fribourg, Switzerland; 6. Department of Medicine, Harvard Medical School, Boston, USA; 7. Department of Neurology, Washington University in St. Louis, St. Louis, USA; 8. Division of Environmental Genomics and Systems Biology, Lawrence Berkeley National Laboratory, Berkeley, USA; 9. UK Dementia Research Institute at University College London, London, UK; 10. Sage Bionetworks, Seattle, USA; 11. Electronics and Mechatronics Department, Facultad de Ingenieria, Universidad Nacional de Asuncion, Luque, Paraguay; 12. Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, USA; 13. Tesabio.ai, Boston, USA; 14. Department of Neurology and Neurological Sciences, Stanford University, Stanford, USA; 15. Institute for Protein Design, University of Washington, Seattle, USA; 16. Department of Radiology, Washington University in St. Louis, St. Louis, USA; 17. Department of Psychological and Brain Sciences, Washington University in St. Louis, St. Louis, USA; 18. Department of Genetics and McDonnell Genome Institute, Washington University in St. Louis, St. Louis, USA; 19. Department of Neurology, University of Minnesota Medical School, Minneapolis, USA; 20. The 10, 000 Brains Project, Oakland, USA; 21. Department of Neurology, University of Washington, Seattle, USA展开收起
PDF源文件 DOI 网页
394 天

Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancer

作者
Marina C. Garassino; Myung-Ju Ahn; Markus Schick; Ansh Kapil; Luis Paz-Ares; Aaron Lisberg; Melissa L. Johnson; Maurice Pérol; Toshio Shimizu; Rebecca Heist; Alexander Spira; Isamu Okamoto; Nicolas Girard; Robin Cornelissen; Elvire Pons-Tostivint; Min Hee Hong; Ricardo Zwirtes; Rachel Chiaverelli; Marlon Rebelatto; Matthew Sung; Chuyu Deng; James Harper; Danielle Carroll; Hadassah Sade; Jacob Sands展开收起
作者单位
1. The University of Chicago, Chicago, USA; 2. Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; 3. Computational Pathology, AstraZeneca, Munich, Germany; 4. Universidad Complutense and CiberOnc, Hospital Universitario 12 de Octubre, Madrid, Spain; 5. Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, USA; 6. Sarah Cannon Research Institute, Nashville, USA; 7. Léon-Bérard Cancer Center, Lyon, France; 8. National Cancer Centre Hospital, Kansai Medical University Hospital, Hirakata, Japan; 9. Massachusetts General Hospital, Boston, USA; 10. Virginia Cancer Specialists (VCS) Research Institute, Fairfax, USA; 11. Kyushu University Hospital, Fukuoka, Japan; 12. Institut Curie, Paris, France; 13. Erasmus MC Cancer Institute, Rotterdam, the Netherlands; 14. University Hospital of Nantes, Nantes, France; 15. Yonsei Cancer Center, Severance Hospital, Seoul, Republic of Korea; 16. Clinical Development, Daiichi Sankyo, Basking Ridge, USA; 17. Pfizer, Inc., New York, USA; 18. Translational Medicine, Daiichi Sankyo, Basking Ridge, USA; 19. GlaxoSmithKline Oncology Translational Medicine, Philadelphia, USA; 20. Translational Pathology, AstraZeneca, Gaithersburg, USA; 21. Oncology Targeted Discovery, AstraZeneca, Waltham, USA; 22. Biometrics, Oncology R&D, AstraZeneca, Boston, USA; 23. Translational Medicine, Oncology R&D, AstraZeneca, Cambridge, UK; 24. GlaxoSmithKline Oncology Translational Medicine, Stevenage, UK; 25. Dana-Farber Cancer Institute, Boston, USA展开收起
PDF源文件 DOI 网页
400 天

Blood-based RNA biomarker for the early detection of ovarian cancer

作者
Jochen Wilhelm; Amit Kumar; Hitesh Vasiyani; Narsimha Mamidi; Zhaoyu Sun; Aenya Gogna; Praveen Bhoopathi; Keshav C. Gogna; Chelsea Salyer; Amy Lu; Kranthi Kumar Chougoni; Ava N. Gardner; Andrew S. Poklepovic; Masaki Nagane; Kumari S. Shree; Emad A. Rakha; Karuppaiyah Selvendiran; George L. Maxwell; Jamie N. Bakkum-Gamez; Shariska Petersen Harrington; Elnaz Abbasi Farid; Nadia Traficante; David Bowtell; Christopher D. Collier; Rebecca Z. Drexler; Christine Kramer; Mary M. Mullen; Alexandar Tzankov; Kirsten D. Mertz; Jun Watanabe; Shimpei Nagai; Tatsuyuki Chiyoda; Wataru Yamagami; Kenta Masuda; Elena Garre; Göran Landberg; David L. Kolin; Calla O’Connor; Sarah A. Ackroyd; Bodour Salhia; Paola A. Gehrig; Aanya Singh; Tytus Bernas; Anusha Challa; Sriram Sriperumbuduri; Nolan A. Wages; Jordan Lewis; Lien Hoang; Janice S. Kwon; Jasmin D. Haslbauer; Mark P. Kühnel; T. Rinda Soong; Sarah Taylor; Carlos Zuazo; Tiffany Beck; Michael J. Demeure; Marc R. Radke; Sourat Darabi; Denise Connolly; Barbara S. Norquist; Nozomi Yachida; Kazuaki Suda; Kosuke Yoshihara; Tu-Yung Chang; Patrick Martin; Kyoung Jae Won; Tian-Li Wang; Ie-Ming Shih; Thomas Russell Pisanic; Tanvir K. Dhaliwal; Vandanaa Jayaprakash; Bukola Adeshina; Seungpyo Hong; Ana Blanca; David R. Braxton; Cesar M. Castro; Elizabeth M. Swisher; Allan Tsung; Ernst Lengyel; Susan Domchek; William L. Redmond; Yonglun Luo; Ole Mogensen; Robert A. Winn; Bo R. Rueda; Ronny Drapkin; Andrew K. Godwin; Ronald J. Buckanovich; Kenneth P. Nephew; Rafael J. Luque; Antonio Lopez-Beltran; Robert L. Coleman; Daniel Von Hoff; David Sidransky; Maximilian Ackermann; Danny Jonigk; Steven R. Grossman; Ranjit Manchanda; Rajan Gogna; Esha Madan展开收起
作者单位
1. Institute for Lung Health (ILH), Universities Giessen & Marburg Lung Center (UGMLC), German Center for Lung Research (DZL), Justus-Liebig-University Giessen, Giessen, Germany; 2. Cell Competition in Tumour Microenvironment Laboratory, Hoag Family Cancer Institute, Newport Beach, USA; 3. Wisconsin Center for NanoBioSystems, School of Pharmacy, University of Wisconsin, Madison, USA; 4. Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, USA; 5. Sage Hill School, Newport Coast, USA; 6. Massey Comprehensive Cancer Center, Virginia Commonwealth University, Richmond, USA; 7. Department of Precision Medicine, Hoag Family Cancer Institute, Newport Beach, USA; 8. Department of Biochemistry, School of Veterinary Medicine, Azabu University, Kanagawa, Japan; 9. Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Nottingham, UK; 10. Nottingham Breast Cancer Research Centre, School of Medicine, Academic Unit for Translational Medical Sciences, University of Nottingham, Nottingham, UK; 11. Division of Gynecologic Oncology, Department of Obstetrics/Gynecology, Comprehensive Cancer Center, The Ohio State University Wexner Medical Center, Columbus, USA; 12. Inova Women’s Service Line and the Inova Schar Cancer Institute, Falls Church, USA; 13. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, USA; 14. Mayo Clinic Hospital, Methodist Campus, Rochester, USA; 15. Indiana University School of Medicine-Bloomington, Indiana University, Bloomington, USA; 16. Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, USA; 17. Peter MacCallum Cancer Centre, Melbourne, Australia; 18. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia; 19. Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, USA; 20. Division of Endocrinology, Metabolism and Lipid Research, John T. Milliken Department of Medicine, Washington University, St. Louis, USA; 21. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, USA; 22. Institute of Medical Genetics and Pathology, University Hospital Basel and University of Basel, Basel, Switzerland; 23. Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan; 24. Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden; 25. Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, USA; 26. Department of Obstetrics and Gynecology, University of Chicago, Chicago, USA; 27. Department of Translational Genomics, Keck School of Medicine, University of Southern California, Los Angeles, USA; 28. Department of Obstetrics and Gynecology, University of Virginia, Charlottesville, USA; 29. Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; 30. Division Gynecology Oncology, Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada; 31. Institute of Pathology, RWTH Aachen Medical University, Aachen, Germany; 32. Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research (DZL), Hannover Medical School, Hanover, Germany; 33. Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, USA; 34. Department of Obstetrics and Gynecology, University of Pittsburgh School of Medicine, Pittsburgh, USA; 35. Department of Obstetrics and Gynecology, University of Washington, Seattle, USA; 36. Fox Chase Cancer Center, Biosample Repository Facility, Philadelphia, USA; 37. Department Obstetrics and Gynecology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; 38. Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, Baltimore, USA; 39. Department of Computational Biomedicine, Cedars-Sinai Medical Center, Los Angeles, USA; 40. Departments of Pathology and Oncology, Johns Hopkins University School of Medicine, Baltimore, USA; 41. The Johns Hopkins Institute for Nanobiotechnology, Johns Hopkins School of Medicine, Baltimore, USA; 42. Joan C. Edwards School of Medicine, Marshall University, Huntington, USA; 43. Pharmaceutical Sciences Division, School of Pharmacy, University of Wisconsin, Madison, USA; 44. Carbone Cancer Center, School of Medicine and Public Health, University of Wisconsin—Madison, Madison, USA; 45. Department of Morphological Sciences, Cordoba University Medical School, Cordoba, Spain; 46. Center for Systems Biology, Massachusetts General Hospital Research Institute, Boston, USA; 47. Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA; 48. Department of Surgery, Division of Surgical Oncology, University of Virginia, Charlottesville, USA; 49. Penn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA; 50. Department of Biomedicine, Aarhus University, Aarhus, Denmark; 51. Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark; 52. Fox Chase Cancer Center, Temple Health, Philadelphia, USA; 53. Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Harvard Medical School, Boston, USA; 54. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, USA; 55. Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, USA; 56. Kansas Institute for Precision Medicine, University of Kansas Medical Center, Kansas City, USA; 57. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, UPMC Hillman Cancer Center and the Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, USA; 58. Department of Medicine, University of Pittsburgh, Pittsburgh, USA; 59. Pathological Anatomy Unit, University Hospital of Jaén, Jaén, Spain; 60. Department of Pathology, Cordoba University Medical School, Cordoba, Spain; 61. Centro Clínico Champalimaud, Lisboa, Portugal; 62. Department of Surgery, Cordoba University Medical School, Cordoba, Spain; 63. Gynecologic Oncology, Texas Oncology, The Woodlands, USA; 64. The Translational Genomics Research Institute, Phoenix, USA; 65. Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, USA; 66. Institute of Functional and Clinical Anatomy, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany; 67. Institute of Pathology and Molecular Pathology, Helios University Clinic Wuppertal, University of Witten/Herdecke, Wuppertal, Germany; 68. Department of Gynaecological Oncology, Barts Health NHS Trust, Royal London Hospital, London, UK; 69. Department of Health Services Research, Faculty of Public Health & Policy, London School of Hygiene & Tropical Medicine, London, UK; 70. Centre for Cancer Screening, Prevention & Early Diagnosis (CCSPED), Wolfson Institute of Population Health, Queen Mary University of London, London, UK展开收起
PDF源文件 DOI 网页
72 天

Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial

作者
Daniel J. Green; Andrew Haynes; Destiny R. Underwood; Evangeline R. Winterton; Abbey A. Green; Robin M. Daly; Elena S. George; Leanne Lester; Louise H. Naylor; Graham S. Hillis; P. Gerry Fegan; Bu B. Yeap展开收起
作者单位
1. School of Human Sciences (Exercise and Sport Science), University of Western Australia, Perth, Australia; 2. The Healthspan Institute, University of Western Australia, Perth, Australia; 3. Institute of Sport, Manchester Metropolitan University, Manchester, UK; 4. Deakin Institute for Physical Activity and Nutrition, School of Exercise and Nutrition Sciences, Deakin University, Geelong, Australia; 5. Centre for Social Impact, University of Western Australia, Perth, Australia; 6. Medical School, University of Western Australia, Perth, Australia; 7. Department of Cardiology, Royal Perth Hospital, Perth, Australia; 8. Medical School, Curtin University, Perth, Australia; 9. Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, Australia展开收起
PDF源文件 DOI 网页
27 天

Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial

作者
Martin Reck; Ernest Nadal; Carl M. Gay; Nicolas Girard; Andrea Riccardo Filippi; Linda W. Martin; Cordula Petersen; David A. Cairns; Margarita Majem; Andrea Ardizzoni; Rosa Alvarez Alvarez; Andrew Robinson; Benoit Roch; Arnaud Boyer; Ilaria Attili; Maximilian Diehn; David Kurtz; Ugochinyere A. Emeribe; Ignacio Diaz Perez; Matteo Giaj Levra; Davina Gale; Zhou Zhu; Nefeli Georgoulia; Jonathan Spicer展开收起
作者单位
1. Lung Clinic Großhansdorf, Airway Research Center North, German Center for Lung Research, Großhansdorf, Germany; 2. Department of Medical Oncology, Institut Català d’Oncologia (ICO), IDIBELL, Bellvitge Healthcare Campus, L’Hospitalet de Llobregat, Barcelona, Spain; 3. Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, USA; 4. Institut du Thorax Curie-Montsouris, Institut Curie/UVSQ, Paris, France; 5. Radiation Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 6. Department of Oncology, University of Milan, Milan, Italy; 7. Division of Thoracic Surgery, Department of Surgery, University of Virginia, Charlottesville, USA; 8. Department of Radiotherapy and Radiation Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 9. Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK; 10. Department of Medical Oncology, Institut de Recerca Sant Pau (IR Sant Pau), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 11. Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 12. Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; 13. Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; 14. Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, Canada; 15. Centre Hospitalier Universitaire de Montpellier, Montpellier, France; 16. Hôpital Saint Joseph, Marseille, France; 17. Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy; 18. Department of Radiation Oncology, Stanford University, Stanford, USA; 19. Division of Oncology, Department of Medicine, Stanford University, Stanford, USA; 20. AstraZeneca, Wilmington, USA; 21. AstraZeneca, Gaithersburg, USA; 22. AstraZeneca, Cambridge, UK; 23. Department of Thoracic Surgery, McGill University, Montreal, Canada展开收起
PDF源文件 DOI 网页

FAQ

NATURE MEDICINE审稿要多久?

截至2026-11-18,CrushSCI 收录了 NATURE MEDICINE 的 20 篇完整审稿记录。最快一篇从收稿到录用用了 21 天(Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial,2026-09-10 收稿,2026-10-01 录用),最慢一篇用了 423 天;平均 194.6 天,中位数 195.5 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。